Cargando…
Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient
INTRODUCTION: Coronavirus disease-2019 (COVID) in patients with advanced heart failure presents unprecedented challenges in management of cardiogenic shock. Recommendations for perioperative triaging of cardiac surgery have been proposed but none regarding LVAD implantation. To our knowledge, we are...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979386/ http://dx.doi.org/10.1016/j.healun.2021.01.1300 |
_version_ | 1783667273361260544 |
---|---|
author | Dib, E.P. Joseph, S. Patel, N. Rafael, A. Meyer, D. Bindra, A. Hall, S. Gong, T. |
author_facet | Dib, E.P. Joseph, S. Patel, N. Rafael, A. Meyer, D. Bindra, A. Hall, S. Gong, T. |
author_sort | Dib, E.P. |
collection | PubMed |
description | INTRODUCTION: Coronavirus disease-2019 (COVID) in patients with advanced heart failure presents unprecedented challenges in management of cardiogenic shock. Recommendations for perioperative triaging of cardiac surgery have been proposed but none regarding LVAD implantation. To our knowledge, we are the first to report on LVAD implantation in a patient with COVID and cardiogenic shock CASE REPORT: A 37-year-old-male with Stage D, NYHA class IV heart failure on chronic milrinone was admitted for cardiogenic shock. Despite uptitration of milrinone and addition of dobutamine,the patient remained in cardiogenic shock . Our Selection Committee discussed and approved him for an LVAD. Institutional protocol required COVID screening prior to surgery and returned positive. Given the absence of clinical signs of COVID infection contrasted with the severity of shock, the decision was made to proceed with implantation. Temporary mechanical support was considered but not thought to mitigate risks of thrombosis rather adding procedural risk with ECMO cannulation and left ventricular unloading. He successfully underwent LVAD implantation as INTERMACS 1. He required high doses of heparin to achieve ACT for cardiopulmonary bypass. On day 2, he developed left-sided weakness with imaging revealing multifocal acute cerebral infarcts. Despite normal LVAD function, the embolic infarcts to multiple organs led to further deterioration and death SUMMARY: LVAD implantation in COVID patients appears inevitable. Centers must risk stratify this cohort to reduce susceptibility to thrombosis and improve outcomes. We propose an algorithm that triages patients for elective and urgent LVAD implantation based on specific coagulation and inflammatory markers (figure 1) and have successfully implanted an LVAD in a COVID patient using this. We acknowledge this method has not been validated in a large cohort and are unable to recommend anticoagulation protocols. Further research is necessary to address safety of LVAD implantation in COVID patients |
format | Online Article Text |
id | pubmed-7979386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79793862021-03-23 Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient Dib, E.P. Joseph, S. Patel, N. Rafael, A. Meyer, D. Bindra, A. Hall, S. Gong, T. J Heart Lung Transplant 1183 INTRODUCTION: Coronavirus disease-2019 (COVID) in patients with advanced heart failure presents unprecedented challenges in management of cardiogenic shock. Recommendations for perioperative triaging of cardiac surgery have been proposed but none regarding LVAD implantation. To our knowledge, we are the first to report on LVAD implantation in a patient with COVID and cardiogenic shock CASE REPORT: A 37-year-old-male with Stage D, NYHA class IV heart failure on chronic milrinone was admitted for cardiogenic shock. Despite uptitration of milrinone and addition of dobutamine,the patient remained in cardiogenic shock . Our Selection Committee discussed and approved him for an LVAD. Institutional protocol required COVID screening prior to surgery and returned positive. Given the absence of clinical signs of COVID infection contrasted with the severity of shock, the decision was made to proceed with implantation. Temporary mechanical support was considered but not thought to mitigate risks of thrombosis rather adding procedural risk with ECMO cannulation and left ventricular unloading. He successfully underwent LVAD implantation as INTERMACS 1. He required high doses of heparin to achieve ACT for cardiopulmonary bypass. On day 2, he developed left-sided weakness with imaging revealing multifocal acute cerebral infarcts. Despite normal LVAD function, the embolic infarcts to multiple organs led to further deterioration and death SUMMARY: LVAD implantation in COVID patients appears inevitable. Centers must risk stratify this cohort to reduce susceptibility to thrombosis and improve outcomes. We propose an algorithm that triages patients for elective and urgent LVAD implantation based on specific coagulation and inflammatory markers (figure 1) and have successfully implanted an LVAD in a COVID patient using this. We acknowledge this method has not been validated in a large cohort and are unable to recommend anticoagulation protocols. Further research is necessary to address safety of LVAD implantation in COVID patients Published by Elsevier Inc. 2021-04 2021-03-20 /pmc/articles/PMC7979386/ http://dx.doi.org/10.1016/j.healun.2021.01.1300 Text en Copyright © 2021 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | 1183 Dib, E.P. Joseph, S. Patel, N. Rafael, A. Meyer, D. Bindra, A. Hall, S. Gong, T. Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient |
title | Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient |
title_full | Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient |
title_fullStr | Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient |
title_full_unstemmed | Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient |
title_short | Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient |
title_sort | left ventricular assist device implantation in a covid-19 positive patient |
topic | 1183 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979386/ http://dx.doi.org/10.1016/j.healun.2021.01.1300 |
work_keys_str_mv | AT dibep leftventricularassistdeviceimplantationinacovid19positivepatient AT josephs leftventricularassistdeviceimplantationinacovid19positivepatient AT pateln leftventricularassistdeviceimplantationinacovid19positivepatient AT rafaela leftventricularassistdeviceimplantationinacovid19positivepatient AT meyerd leftventricularassistdeviceimplantationinacovid19positivepatient AT bindraa leftventricularassistdeviceimplantationinacovid19positivepatient AT halls leftventricularassistdeviceimplantationinacovid19positivepatient AT gongt leftventricularassistdeviceimplantationinacovid19positivepatient |